Guselkumab
Indication
For treating active psoriatic arthritis after inadequate response to DMARDs.
NICE TA711 - Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs
Red
Brand:
Nice TA:
711
Commissioning responsibility:
CCG
PbR excluded:
Yes
BNF chapter:
Skin
Background
1.1 Guselkumab, alone or with methotrexate, is recommended as an option for treating active psoriatic arthritis in adults whose disease has not responded well enough to disease-modifying antirheumatic drugs (DMARDs) or who cannot tolerate them, only if they have:
- peripheral arthritis with 3 or more tender joints and 3 or more swollen joints
- moderate to severe psoriasis (a body surface area of at least 3% affected by plaque psoriasis and a Psoriasis Area and Severity Index [PASI] score greater than 10)
- had 2 conventional DMARDs and at least 1 biological DMARD.
Guselkumab is recommended only if the company provides it according to the commercial arrangement.